KRAS and non-small cell lung carcinoma: Extended to a clinical application, a comparison of the relevance with clinical observations showing that patients with CRC derive less benefit compared with those with NSCLC from a KRAS inhibitor [38], may indicate that a hypoxia-dependent complex signaling pathway should be taken into consideration in KRAS-mutant cancer research.